Pfizer Stalls Celltech Deal, Wants Bigger Profit Share

Celltech Group plc said partner Pfizer Inc. has decided to delay development of the rheumatoid arthritis drug CDP 870, thereby stalling the potential launch for at least one year, and wants to renegotiate the terms of the companies' profit-sharing agreement. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)